Myfortic® versus Neoral® as long-term treatment in patients with severe atopic dermatitis: a randomised-controlled trial

INTERVENTION: After initial treatment of 6 weeks with Neoral® 5 mg/kg for all patients, there is a randomisation in two groups. One group is treated with Neoral® 3 mg/kg and the other group with Myfortic® 1440 mg. CONDITION: Atopic dermatitis ; Skin and Connective Tissue Diseases ; Atopic dermatitis PRIMARY OUTCOME: Clinical severity score (Local Leverity Score [LSS]) SECONDARY OUTCOME: 1. Physician Global Assessment Score (PGA); 2. Serum levels of thymus and activation and regulated chemokine (TARC); 3. Itch (Visual Analogue Score [VAS]); 4. Amount of topical steroids that is used; 5. Quality of life, measured with the Dermatology Life Quality Index (DLQI) of Finlay INCLUSION CRITERIA: 1. Aged from 18 years 2. Atopic dermatitis according to the criteria of Hanifin and Rajka 3. Insufficient response to topical treatment alone 4. The physician estimates that treatment with oral immunosuppressive agents is indicated